Illumina, Inc. announced today that Mark Van Oene has been named Chief Commercial Officer. Van Oene was previously Illumina’s Senior Vice President of the Americas region and subsequently named interim Chief Commercial Officer in late 2016.
“Mark is a great leader for our commercial organization, possessing deep genomics expertise and over a decade of experience building and running strong sales and marketing teams,” said Francis deSouza, Illumina President and Chief Executive Officer. “As interim Chief Commercial Officer Mark has guided Illumina through two strong quarters, including the launch of NovaSeq, and laid the foundation for our future growth. I am excited to continue to work closely with Mark to expand our commercial capability as we grow in research and clinical markets around the world.”
Van Oene joined Illumina in 2006 as Regional Account Manager for Canada. In 2008, Van Oene was promoted to Senior Director of Sales for the Americas. Four years later, he was promoted to Vice President with responsibility for global sales. From 2012 through 2014, Van Oene led the team to grow revenues from $1.06B to $1.42B. In early 2014, Van Oene was named the General Manager for the Americas region, advancing to Senior Vice President in April 2016. During that time, the Americas compound annual growth rate exceeded 20%.
As Chief Commercial Officer, Van Oene will be responsible for world-wide sales, services and marketing at Illumina. He will report to President and CEO, Francis deSouza.
Van Oene earned a Bachelor of Science degree in Biochemistry from Western University in London, Ontario, Canada.
Big Pharma has long seen the potential for AI and machine learning to accelerate drug development. But Novo Nordisk is going a step further by channeling $200 million toward the creation of a computer that will outrun anything in existence.
Current methods for diagnosing Alzheimer’s disease rely on a complex combination of self- and caregiver-reported symptoms, a physical examination and either a PET scan or a spinal tap to look for evidence of amyloid plaque build-ups in the brain. But a new artificial intelligence-based method may make the diagnostic process a much more objective one.
There is lots of talk about diversity and inclusion in business, including in pharma and medtech. A new report by the Open Political Economy Network (OPEN), a think tank focusing on migration and diversity, released its “Minority Businesses Matter: Europe” report highlighting the successes and challenges of ethnic minority-owned businesses in Europe.